GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022 – Yahoo Finance


PARIS, June 16, 2022–(BUSINESS WIRE)–Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it will participate to the EUNOS 2022 meeting, which is taking place on June 20-23 in Birmingham, United Kingdom. The conference is the most important conference in Europe for neuro-ophthalmologists and provides GenSight the opportunity to discuss its clinical data and recent developments with the neuro-ophthalmology community. The Company is a sponsor of EUNOS and will have a booth on site.
Patrick Yu-Wai-Man, MD, PhD, Professor of Ophthalmology and Honorary Consultant Neuro-ophthalmologist at the University of Cambridge, Moorfields Eye Hospital, and the UCL Institute of Ophthalmology, United Kingdom, will present on two topics relevant to Leber Hereditary Optic Neuropathy (LHON). He will first present data from GenSight’s Phase III REFLECT trial and discuss the efficacy of the Company’s bilateral treatment approach. He will also discuss the future of LHON treatment.
"The long-term follow-up data of patients in the REFLECT trial illustrate the sustained effect of the treatment and the clear impact on visual acuity for patients affected with LHON", he said. "The data will be of particular interest to physicians seeking an effective treatment for this blinding mitochondrial disorder."
15th annual meeting of EUNOS (European Neuro-Ophthalmological Society) – EUNOS 2022
June 20-23, 2022 – University of Birmingham, Edgbaston, Birmingham, UK
"The Phase III REFLECT trial: efficacy of bilateral gene therapy for Leber Hereditary Optic Neuropathy (LHON) is maintained 2 years post administration," presented by Patrick Yu-Wai-Man, MD, PhD, University of Cambridge, United Kingdom (principal investigator in the RESCUE, REVERSE, RESTORE, REFLECT and REALITY trials; international coordinator of the REVERSE trial).
Oral Presentation
Free Papers 1
Tuesday, June 21, 2022, 2:00 pm BST
"Future Treatment for Leber’s hereditary optic neuropathy," presented by Patrick Yu-Wai-Man, MD, PhD, University of Cambridge, United Kingdom (principal investigator in the RESCUE, REVERSE, RESTORE, REFLECT and REALITY trials; international coordinator of the REVERSE trial).
Oral Presentation
Inherited Optic Neuropathies
Wednesday, June 22, 2022, 3:00 pm BST
GenSight Biologics will also lead a presentation on GS010 (Lenadogene nolparvovec) clinical data at the Global 7th Cell & Gene Therapy Summit, July 19-21. Magali TAIEL, MD, Chief Medical Officer of GenSight Biologics, will make a presentation titled, "Development of GS010 gene therapy in Leber Hereditary Optic Neuropathy: Key learnings".
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005867/en/
Contacts
GenSight Biologics
Corporate Communications Director
Clothilde Caillet
[email protected]
LifeSci Advisors
Investor Relations
Guillaume van Renterghem
[email protected]
+41 (0)76 735 01 31
RooneyPartners
Media Relations
Jeanene Timberlake
[email protected]
+1 646-770-8858
Orpheon Finance
Retail Investors
James Palmer
[email protected]
+33 (0)7 60 92 77 74
Related Quotes
There were no surprises in the FDA's assessment of an Alzheimer's drug from Acadia Pharmaceuticals, and ACAD stock surged Wednesday.
Clovis Oncology Inc (NASDAQ: CLVS) announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286). Overall, in nine patients treated in the first two dose cohorts, 177Lu-FAP-2286 demonstrated a manageable safety profile and encouraging evidence of activity, including a confirmed RECIST partial response in one patient. A confirmed RECIST partial response was reported in one heavily pre-treated patient in the 3.7
Florida’s Department of Health is led by state Surgeon General Joe Ladapo, an outspoken skeptic of the Covid-19 vaccine.
Pfizer’s (PFE) COVID-19 antiviral Paxlovid isn’t effective for people who are vaccinated and healthy. The company on Tuesday shared updated data from a Phase 2/3 clinical trial evaluating Paxlovid, saying that the antiviral does not help reduce symptoms in people who are considered “standard risk” for a severe COVID-19 infection, hospitalization, or death, as had been previously reported. It also said Paxlovid did not have a significant impact on high-risk people who have been vaccinated.
Pfizer's Paxlovid and Merck's Lagevrio can prevent cases of COVID from turning truly serious.
Pfizer Inc (NYSE: PFE) shared additional data from the Phase 2/3 EPIC-SR study of Paxlovid (nirmatrelvir and ritonavir tablets) in patients at standard risk for developing severe COVID-19. In previously reported interim analyses, the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met. Non-significant 70% relative risk reduction was observed in the key secondary endpoint of hospitalization or death. Related: Pfizer, NIH Mulling Stu
FDA advisors unanimously endorsed Moderna's and Pfizer's Covid shots for children on Wednesday, prodding the vaccine stocks to rise.
Moderna has finally moved one step closer to authorization of its COVID-19 vaccine for two additional age groups, 6-11 years and 12-17 years, after an U.S. Food and Drug Administration advisory committee voted unanimously to recommend the doses Tuesday.
Most patients with the most common form of childhood brain cancer saw their tumors shrink by half. Now the company, which hopes to ask regulators next year to approve the drug, is eyeing a big fundraise as a result.
A year and a half after the authorization of the first Covid-19 vaccines in the U.S., children under 5 years old are on their way to being able to be vaccinated. The Food and Drug Administration’s vaccines advisers on Wednesday unanimously backed authorization both of a two-dose series of Moderna (ticker: MRNA) Covid-19 vaccine for children aged six months to five years, and a three-dose series of Pfizer (PFE) vaccine for children aged six months to four years. Now, the FDA itself must choose whether to take its advisers’ recommendation.
Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and other innovative treatments for people living with depression and related mental health disorders, is pleased to announce today the opening of its newest Braxia Health clinic in the Kitchener-Waterloo area in Ontario. The Kitchen-waterloo location is the fifth Braxia Health Clinic in Canada.
A new cancer drug, created by a doctor at the OU College of Medicine, will be tested in humans as part of a Phase 1 clinical trial.
If all the regulatory steps are cleared, the shots should be available next week.
FDA's advisory committee checked the first of four boxes that would allow COVID-19 vaccines for kids 5 and under to be authorized in the U.S. Wednesday.
The Food and Drug Administration's vaccine advisers gave a thumbs-up to vaccines from Moderna and Pfizer for the littlest kids. The outside experts voted unanimously that the benefits of the shots outweigh any risks for children under 5 — that’s roughly 18 million youngsters. “This is a long-awaited vaccine,” said one panel member, Dr. Jay Portnoy of Children’s Hospital in Kansas City, Missouri.
Advisors to the FDA unanimously Tuesday recommended expanding Moderna's Covid vaccine to children as young as 6.
The Food and Drug Administration is now expected to authorize two COVID-19 vaccines for children as young as six months old.
The drug has emergency use authorization for high-risk groups in which it has been effective in reducing hospitalizations and deaths. The new data, however, showed a 51% relative risk reduction in standard-risk groups, which the company said was not statistically significant. Pfizer said it will include the new data in the company's upcoming application to the U.S. Food and Drug Administration seeking full approval for the drug's use in high-risk groups.
Story at a glance The Maryland-based company Novavax has a COVID-19 vaccine that is approved for emergency use internationally but not yet in the U.S. The FDA’s Advisory Committee has recommended it be granted emergency use authorization. The manufacturing process follows more traditional vaccine production and can be slower to build up supply. Last week,…
The Food and Drug Administration (FDA) has approved a full-body treatment for alopecia areata, an autoimmune disorder that can cause hair loss and baldness occurring in patches on the body, for the first time. The FDA announced in a release Monday that it has approved oral tablets called Olumiant as a treatment for adults with…

source


Leave a Reply

Your email address will not be published.